STELLAR safety results

No systemic AEs were considered to be related to the use of Optune Lua1

  • Mild-to-moderate skin irritation was the only device-related side effect attributed to the use of Optune Lua

Severe (Grade 3-4) AEs by body system seen in >1 patient:

System organ class/
preferred term
Optune Lua and
pemetrexed + cisplatin
or carboplatin
(N=80)
Number of patients with ≥1 AE 32 (40%)
Blood and lymphatic system disorders
Anemia
Leukopenia
Neutropenia
Thrombocytopenia
18 (23%)

9 (11%)
3 (4%)
7 (9%)
4 (5%)
Cardiac disorders
Pericardial effusion
3 (4%)
2 (3%)
Gastrointestinal disorders
Vomiting
3 (4%)
2 (3%)
System organ class/
preferred term
Optune Lua and
pemetrexed + cisplatin
or carboplatin
(N=80)
General disorders and
administration site conditions
Fatigue
6 (8%)
3 (4%)
Infections and infestations 2 (3%)
Investigations 2 (3%)
Respiratory, thoracic, and mediastinal disorders
Dyspnea

4 (5%)
2 (3%)
Skin and subcutaneous tissue disorders
Medical device site reaction
(rash beneath transducer arrays)
4 (5%)
4 (5%)

The only AE attributed to Optune Lua use was skin irritation (71% of patients); 66% mild-to-moderate and 5% severe.1,2

  • No SAEs were considered related to device use

Proper skin care is important for patients using Optune Lua

  • Proactive management can help patients prevent common causes of skin irritation and infection
  • Discuss with your patients how to properly care for their skin while using Optune Lua
  • Download the skin care guidelines for your patients
Download here

AEs, adverse events; SAEs, serious adverse events.

References: 1. Optune Lua. Instructions for Use for Unresectable Malignant Pleural Mesothelioma. Novocure; 2019. 2. Ceresoli GL, Aerts JG, Dziadziuszko R, et al. Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial. Lancet Oncol. 2019;20(12):1702-1709.

Next: The Optune Lua system
Indications For Use
jump to isi

The Optune Lua System is indicated for the treatment of adult patients with unresect…

Leaving OptuneLua.com

Novocure® does not review the information contained on this website and/or database for content, accuracy, or completeness. Use of and access to this information is subject to the terms, limitations, and conditions set by the website and/or database producer.

Novocure makes no representation as to the accuracy or any other aspect of the information contained on such website and/or database, nor does Novocure necessarily endorse such website and/or database.